Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a ...

Now looking beyond NASH, PEMB has the potential to address major unmet medical needs in both AUD and ALD because of a similar ...

Xenon Pharmaceuticals Inc. jumps on Phase 3 azetukalner seizure data; NDA planned Q3 2026. Click for more on XENE stock and why I am neutral on it now.

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006 ...

The IRS has pointed out the most common errors taxpayers make as they file their taxes, from something as seemingly small as a misspelled name to accidentally entering the wrong bank account number ...